Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor

Am J Hematol. 2007 May;82(5):417-8. doi: 10.1002/ajh.20764.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • ADAM Proteins / immunology*
  • ADAMTS13 Protein
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy
  • Female
  • Humans
  • Plasma Exchange
  • Pregnancy
  • Pregnancy Complications, Hematologic / immunology
  • Pregnancy Complications, Hematologic / therapy
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Purpura, Thrombotic Thrombocytopenic / immunology
  • Purpura, Thrombotic Thrombocytopenic / therapy
  • Rituximab
  • Secondary Prevention

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies
  • Rituximab
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human